Skip to main content
SpringerLink
Log in

Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Recent preclinical and clinical studies indicate that aldosterone, independent of angiotensin II and elevated blood pressure, may play a role in health and disease. In addition to its role in fluid and electrolyte balance and circulatory homeostasis, more recent studies have identified aldosterone as a critical mediator of vascular damage. In animal studies, aldosterone is implicated in cardiac and vascular fibrosis, renal disease, and cerebrovascular damage. These lesions are prevented by specific aldosterone receptor blockade. In clinical studies, aldosterone receptor antagonism is associated with decreased hospitalization, symptomatology, and mortality, and improvement of endothelial dysfunction in patients with chronic heart failure. A better understanding of aldosterone’s actions in nonepithelial tissues should pave the way to better protection of organs at risk such as the kidneys, heart, and brain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chen SY, Bhargava A, Mastroberardino L, et al.: Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A 1999, 96:2514–2519.

    Article  PubMed  CAS  Google Scholar 

  2. Chargava A, Fullerton MJ, Myles K et al.: The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology 2001, 142:1587–1594.

    Article  Google Scholar 

  3. Bravo EL, Fouad-Tarazi FM, Tarazi RC, et al.: Clinical implications of primary aldosteronism with resistant hypertension. Hypertension 1988, 11:I207–211.

    PubMed  CAS  Google Scholar 

  4. Bravo EL, Dustan HP, Tarazi RC: Spironolactone as a nonspecific treatment of primary aldosteronism. Circulation 1973, 48:491–498.

    PubMed  CAS  Google Scholar 

  5. Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med 1999, 131:105–108.

    PubMed  CAS  Google Scholar 

  6. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709–716. This study demonstrated that eplerenone is efficacious in the treatment of mild to moderate hypertension.

    Article  PubMed  CAS  Google Scholar 

  7. Weinberger M, MacDonald T, Conlin PR, et al.: Comparison of eplerenone and losartan in patients with low-renin hypertension [abstract]. Am J Hypertens 2002, 15(4 Pt 2):OR55.

    Article  Google Scholar 

  8. Takeda Y, Miyamori I, Inaba S, et al.: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29:45–48.

    PubMed  CAS  Google Scholar 

  9. Takeda Y, Yoneda T, Demura M, et al.: Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000, 36:495–500.

    PubMed  CAS  Google Scholar 

  10. Gomez-Sanchez CE, Zhou MY, Cozza EN, et al.: Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138:3369–3373.

    Article  PubMed  CAS  Google Scholar 

  11. Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883–4891.

    Article  PubMed  CAS  Google Scholar 

  12. Brody MJ, Varner KJ, Vasquez EC, Lewis SJ: Central nervous system and the pathogenesis of hypertension. Sites and mechanisms. Hypertension 1991, 18:III7-II12.

    PubMed  CAS  Google Scholar 

  13. Gomez-Sanchez EP: Central hypertensive effects of aldosterone. Front Neuroendocrinol 1997, 18:440–462.

    Article  PubMed  CAS  Google Scholar 

  14. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C: ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 1990, 258:E649-E653.

    PubMed  CAS  Google Scholar 

  15. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovas Res 1992, 26:671–677.

    Article  CAS  Google Scholar 

  16. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563–575.

    Article  PubMed  CAS  Google Scholar 

  17. Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871–3878.

    Article  PubMed  CAS  Google Scholar 

  18. Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810. In this study, uninephrectomized rats receiving a high-salt diet and aldosterone developed severe hypertension after 2 weeks of treatment.

    PubMed  CAS  Google Scholar 

  19. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232–237.

    PubMed  CAS  Google Scholar 

  20. Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31(1 Pt2):451–458.

    PubMed  CAS  Google Scholar 

  21. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. A clinical study providing support for the role of aldosterone in cardiac pathophysiology.

    Article  PubMed  CAS  Google Scholar 

  22. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997, 35:30–34.

    Article  PubMed  CAS  Google Scholar 

  23. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594–597.

    PubMed  CAS  Google Scholar 

  24. Rossi GP, Sacchetto A, van E, et al.: Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation 1997, 95:1471–1478.

    PubMed  CAS  Google Scholar 

  25. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730–1736.

    PubMed  CAS  Google Scholar 

  26. Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259–1265.

    Article  PubMed  CAS  Google Scholar 

  27. Struthers AD: Aldosterone escape during angiotensin converting enzyme inhibitor therapy in chronic heart filature. J Cardiac Fail 1996, 2:47–54.

    Article  CAS  Google Scholar 

  28. Yusuf S: Untitled abstract. Circulation 1997, 96:1452A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Cleveland Clinic Foundation, 9500 Euclid Avenue - Desk A51, 44195, Cleveland, OH, USA

    Emmanuel L. Bravo MD

Authors
  1. Emmanuel L. Bravo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bravo, E.L. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Current Science Inc 5, 122–125 (2003). https://doi.org/10.1007/s11906-003-0068-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0068-z

Keywords

Search

Navigation